

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/042,352	01/11/2002	Bernard Charles Sherman	2051-44	2443
23607	7590 06/16/2005		EXAMINER	
IVOR M. HUGHES, BARRISTER & SOLICITOR, PATENT & TRADEMARK AGENTS 175 COMMERCE VALLEY DRIVE WEST			YOUNG, MICAH PAUL	
			ART UNIT	PAPER NUMBER
SUITE 200			1618	
THORNHILL, ON L3T 7P6 CANADA			DATE MAILED: 06/16/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/042,352	SHERMAN, BERNARD CHARLES			
Office Action Summary	Examiner	Art Unit			
	Micah-Paul Young	1618			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above, thes maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status	•				
1) Responsive to communication(s) filed on 11 Fe	ebruary 2005.				
2a) ☐ This action is FINAL . 2b) ☒ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1,6,7 and 11-13 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1,6,7 and 11-13 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 01/11/02	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa				

Application/Control Number: 10/042,352 Page 2

Art Unit: 1618

DETAILED ACTION

Acknowledgment of Papers Received: Request for Continued Examination dated 2/11/05

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 3. Claims 1,6,7, and 11-13 rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Seymour (USPN 5,225,401 hereafter '401), Flynn et al (USPN 5,095,110 hereafter '110) and Jerzewski et al (USPN 5,009,344 hereafter '344). The claims are drawn to a tablet comprising fosinopril sodium and zinc stearate as a lubricant.
- 4. The '401 discloses tablets for treating congestive heart failure (abstract). The tablets comprise well-known ACE inhibitory drugs such as Captopril and fosinopril sodium (abstract).

Art Unit: 1618

The tablets include fillers such as lactose and starch and lubricants such as stearic acid and magnesium stearate (col. 4, lin. 50-58).

- An artisan of ordinary skill would be aware that magnesium stearate would not be advantageous to a fosinopril sodium formulation as seen in '344 (Example 16). With this knowledge an artisan of ordinary skill would choose stearic acid or an equivalent as the lubricant for the ACE inhibitory formulation. As shown in '110 it would have been well within the level of skill in the art to substitute zinc stearate for the stearic acid of '401 (col. 16, lin. 16-20). Since all of the lubricants are well known to artisans of ordinary skill, their selection, elimination and substitution would be well within the level of skill in the art. Barring a showing of unexpected results, it is the position of the Examiner that this substitution would be determined through routine experimentation.
- 6. Regarding the claims reciting specific ranges, it is the position of the Examiner that such limitations would be within the level of skill in the art to obtain as well. Applicant is reminded that where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. *See* In re Aller, 220 F.2d 454 105 USPQ 233, 235 (CCPA 1955).
- Furthermore the claims differ from the reference by reciting various concentrations of the active ingredient(s). However, the preparation of various compositions having various amounts of the active is within the level of skill of one having ordinary skill in the art at the time of the invention. It has also been held that the mere selection of proportions and ranges is not patentable absent a showing of criticality. *See* In re Russell, 439 F.2d 1228 169 USPQ 426 (CCPA 1971).

Application/Control Number: 10/042,352 Page 4

Art Unit: 1618

8. With these things in mind, it would have been obvious to an artisan of ordinary skill to substitute the zinc stearate of '110 for the zinc stearate of '401 following the motivation to avoid magnesium stearate provided by '344. The artisan of ordinary skill would have been motivated to do so in order to provide a stable tablet capable of treating heart disorders. It would have been obvious to one of ordinary skill in the art to follow these motivations and teachings with an expected result of a stable tablet capable of treating cardiac disorders.

Response to Arguments

9. Applicant's arguments with respect to claims 1-10 have been considered but are moot in view of the new ground(s) of rejection.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608. The examiner can normally be reached on M-F 7:00-4:30 every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/042,352 Page 5

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Micah-Paul Young Examiner Art Unit 1618

MP Young

THURMAN K. PAGE SUPERVISORY PATENT EXAMINER -TECHIOLOGY CENTER 1600